Sussex Partner Formulary
  • About The Formulary
  • Using The Formulary
  • Therapeutic Sections
    • 1 Gastro-intestinal system
    • 2 Cardiovascular system
    • 3 Respiratory system
    • 4 Nervous system
    • 5 Infection
    • 6 Endocrine system
    • 7 Genito-urinary system
    • 8 Immune system & malignant disease
    • 9 Blood and nutrition
    • 10 Musculoskeletal system
    • 11 Eye
    • 12 Ear, nose and oropharynx
    • 13 Skin
    • 14 Vaccines
    • 15 Anaesthesia
    • 16 Emergency treatment of poisoning
    • 17 Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum
    • Appendix 1 - Borderline substances
    • Appendix 2 - Wound management products and elasticated garments
    • Appendix 3 - Continence
    • Appendix 4 - Palliative care
  • Drug Index
  • Antimicrobial Guidance
  • Shared Care Protocols
  • Position statements
  • Not Recommended Items
  • APC Summaries
    • 2025
    • 2024
    • 2023
  • APC Minutes
  • Discontinuations
  • Contact us
  • About The Formulary
  • Using The Formulary
  • Therapeutic Sections
    • 1 Gastro-intestinal system
    • 2 Cardiovascular system
      • 2.1 Arrhythmias
      • 2.2 Bleeding disorders
        • 2.2.1 Coagulation factor deficiencies
        • 2.2.2 Subarachnoid haemorrhage
      • 2.3 Blood clots
      • 2.4 Blood pressure conditions
      • 2.5 Cardiovascular risk assessment and prevention
      • 2.6 Heart failure
      • 2.7 Hyperlipidaemia
      • 2.8 Myocardial ischaemia
      • 2.9 Vascular disease
      • 2.10 Other Cardiovascular system items
    • 3 Respiratory system
    • 4 Nervous system
    • 5 Infection
    • 6 Endocrine system
    • 7 Genito-urinary system
    • 8 Immune system & malignant disease
    • 9 Blood and nutrition
    • 10 Musculoskeletal system
    • 11 Eye
    • 12 Ear, nose and oropharynx
    • 13 Skin
    • 14 Vaccines
    • 15 Anaesthesia
    • 16 Emergency treatment of poisoning
    • 17 Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum
    • Appendix 1 - Borderline substances
    • Appendix 2 - Wound management products and elasticated garments
    • Appendix 3 - Continence
    • Appendix 4 - Palliative care
  • Drug Index
  • Antimicrobial Guidance
  • Shared Care Protocols
  • Position statements
  • Not Recommended Items
  • APC Summaries
  • APC Minutes
  • Discontinuations
  • Contact us
  • Search

Drug Status Key

  • Non-Specialist Drugs
  • Specialist recommendation (or initiation where noted)
  • Specialist Initiation WITH Shared Care Guidelines
  • Specialist ONLY Drugs
  • Mixed Status - See individual drug entries for more details

Preferences

  • First Line
  • Second Line
  • Third Line
  • No Preference

Aprotinin

{ Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Aprotinin 500,000 Kallikrein inactivator units/50ml solution for infusion vials

Pack
1 vial

Aprotinin 1,000,000 Kallikrein inactivator units/100ml solution for infusion vials

Pack
1 vial

Aprotinin 2,000,000 Kallikrein inactivator units/200ml solution for infusion vials

Pack
1 vial

Terlipressin

{ Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Terlipressin 1mg powder and solvent for solution for injection vials

Pack
5 vial

Terlipressin 1mg/5ml solution for injection vials

Pack
5 vial

Terlipressin 1mg/8.5ml solution for injection ampoules

Pack
5 ampoule

Tranexamic acid

{ Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Tranexamic acid 500mg tablets

Pack
60 tablet
18 tablet

Tranexamic acid 500mg/5ml solution for injection ampoules

Pack
10 ampoule
5 ampoule

Tranexamic acid 1g/10ml solution for injection ampoules

Pack
5 ampoule
  • 2.2.1 Coagulation factor deficiencies
  • 2.2.2 Subarachnoid haemorrhage

Online Formulary by M.O.M. Systems

NICE guidance is available from https://www.nice.org.uk/guidance All rights reserved. Subject to Notice of rights.
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

© Copyright 2025